Open-Label Study in Healthy Subjects to Evaluate the Safety, Tolerability, and Pharmacokinetics of Switching from Oral Risperidone to Risperidone Implant (DLP-114)
Phase of Trial: Phase I
Latest Information Update: 17 Dec 2018
At a glance
- Drugs Risperidone (Primary)
- Indications Bipolar disorders; Schizophrenia
- Focus Adverse reactions; First in man
- Sponsors Delpor
- 11 Dec 2018 Planned End Date changed from 28 May 2018 to 31 Dec 2019.
- 01 Dec 2017 Status changed from not yet recruiting to recruiting.
- 04 Sep 2017 New trial record